Profil
Mr. Graham Parry is a Research Analyst at Merrill Lynch International.
He is a Managing Director and head of Healthcare equity research.
Based in London, he heads up the European healthcare equity research team with direct coverage responsibility for European large cap pharmaceuticals and biotechnology.
He has headed European pharmaceuticals research since 2004, where he has successfully built out the team to become consistently highly rated in its sector in the Institutional Investor survey.
Mr. Parry initially joined Merrill Lynch in 2003 as Global pharmaceuticals/healthcare specialist sales, joining from ABN Amro where he was a pharmaceutical and biotechnology equity research analyst.
He started his career in equity sales in 1997 at JB Were and Son, now part of Goldman Sachs.
He studied at Oxford University where he gained a master’s degree in Biochemistry.
Postes actifs de Graham Parry
Sociétés | Poste | Début |
---|---|---|
Merrill Lynch International
Merrill Lynch International Investment Banks/BrokersFinance Merrill Lynch International (MLI-UK) is a brokerage firm headquartered in London, UK. The firm was founded in 1988 and is a subsidiary of ML UK Capital Holdings Ltd., ultimately owned by Bank of America Corp. (NYSE: BAC) in the US. MLI-UK provides brokerage services to individual and retail clients. | Analyst-Equity | 01/01/2004 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Merrill Lynch International
Merrill Lynch International Investment Banks/BrokersFinance Merrill Lynch International (MLI-UK) is a brokerage firm headquartered in London, UK. The firm was founded in 1988 and is a subsidiary of ML UK Capital Holdings Ltd., ultimately owned by Bank of America Corp. (NYSE: BAC) in the US. MLI-UK provides brokerage services to individual and retail clients. | Finance |